1.桂林医学院第二附属医院肝胆外科,广西 桂林 541199
2.解放军联勤保障部队第924医院肿瘤科,广西 桂林 541002
3.中山大学附属第一医院肝外科,广东 广州 510080
姚红兵,主任医师,研究方向:肝癌基础及临床研究;E-mail: luckstar0503@163.com
收稿:2021-01-29,
纸质出版:2021-05-20
移动端阅览
姚红兵,肖芳,郭威等.FAK抑制剂对肝癌HCC-LM3细胞骨架重排和侵袭的作用机制[J].中山大学学报(医学科学版),2021,42(03):364-372.
YAO Hong-bing,XIAO Fang,GUO Wei,et al.Effect and Mechanism of FAK Inhibitors on Cytoskeleton Rearrangement, Invasion and Migration of HCC-LM3 Cells[J].Journal of Sun Yat-sen University(Medical Sciences),2021,42(03):364-372.
姚红兵,肖芳,郭威等.FAK抑制剂对肝癌HCC-LM3细胞骨架重排和侵袭的作用机制[J].中山大学学报(医学科学版),2021,42(03):364-372. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2021.0106.
YAO Hong-bing,XIAO Fang,GUO Wei,et al.Effect and Mechanism of FAK Inhibitors on Cytoskeleton Rearrangement, Invasion and Migration of HCC-LM3 Cells[J].Journal of Sun Yat-sen University(Medical Sciences),2021,42(03):364-372. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2021.0106.
目的
2
基于FAK/PI3K/Akt通路,探讨FAK抑制剂CT-707对人肝癌HCC-LM3细胞骨架重排、侵袭、迁移及裸鼠皮下移植瘤生长的影响和机制。
方法
2
HCC-LM3细胞分为Control组、CT-707低剂量(1.5 μmol/L)组、CT-707中剂量(3 μmol/L)组、CT-707高剂量(6 μmol/L)组,采用Transwell小室实验、细胞划痕、MTT实验分别测定细胞侵袭、迁移能力及细胞活力;采用RT-qPCR和Western blot分别检测Palladin、Vimentin、MMP2和MMP9 mRNA及蛋白的表达;Western blot检测p-FAK、FAK、p-PI3K、PI3K、p-Akt及Akt蛋白的表达。使用HCC-LM3细胞系建立裸鼠皮下移植瘤模型,分为模型组、CT-707组(20 mg/kg, 腹腔注射),每组6只,记录肿瘤体积及质量,采用HE染色法观察移植瘤组织结构变化,免疫组化检测移植瘤FAK、PI3K、p-Akt、MMP-2、MMP-9的表达。
结果
2
与Control组比较,CT-707高、中、低剂量组可显著抑制HCC-LM3细胞侵袭迁移能力,降低细胞活力,下调Palladin、Vimentin、MMP2、MMP9、p-FAK/FAK、p-PI3K/PI3K、p-Akt/Akt的表达水平(
P<
0.05),中、高剂量组的效应明显优于低剂量组(
P<
0.05),中、高剂量组间结果差异无统计学意义(
P>
0.05)。与模型组比较,CT-707治疗后可显著降低移植瘤体积和质量以及FAK、PI3K、p-Akt、MMP-2、MMP-9蛋白表达(
P<
0.05),抑瘤率为51.92%。
结论
2
CT-707可能通过抑制FAK/PI3K/Akt信号通路活性,降低细胞骨架重排及基质金属蛋白酶分泌,从而抑制肝癌细胞侵袭、迁移以及肿瘤生长。
Objective
2
To explore the effect of FAK inhibitor CT-707 on the cytoskeleton rearrangement, invasion and migration of human hepatocellular carcinoma cells HCC-LM3 and its mechanism, and the growth of subcutaneous xenografted tumors in nude mice based on the FAK/PI3K/Akt pathway.
Methods
2
HCC-LM3 cells were divided into Control group, CT-707 low dose (1.5 μmol/L) group, CT-707 medium dose (3 μmol/L) group, CT-707 high dose (6 μmol/L) group. Transwell chamber test, cell scratch, and MTT test were used to determine cell invasion, migration and cell viability. RT-qPCR and Western blot were used to detect the mRNA and protein expression of Palladin, Vimentin, MMP2 and MMP9. Western blot was used to detect the expression of p-FAK, FAK, p-PI3K, PI3K, p-Akt and Akt protein. HCC-LM3 cell line was used to establish subcutaneous xenograft tumor models in nude mice, which were divided into model group and CT-707 group (20 mg/kg, ip), with 6 mice in each group. The tumor volume and mass were recorded, the tissue structure changes of the transplanted tumor were observed by HE staining method, and the expression of FAK, PI3K, p-Akt, MMP-2, MMP-9 of the transplanted tumor was detected by immunohistochemistry.
Results
2
Compared with the control group, the CT-707 high, medium and low dose groups could significantly inhibit the invasion and migration ability, decrease cell viability, significantly down-regulate the expression levels of Palladin, Vimentin, MMP2, MMP9, p-FAK/FAK, p-PI3K /PI3K and p-Akt/Akt, (
P<
0.05), and the effect of the middle and high-dose groups was significantly better than that of the low-dose group (
P<
0.05), and there was no significant difference in the results between the middle and high-dose groups (
P>
0.05). Compared with those in the control group, CT-707 could significantly reduce the volume and quality of transplanted tumors and the protein expression of FAK, PI3K, p-Akt, MMP-2, and MMP-9 in the treatment groups (
P
<
0.05), and the tumor inhibition rate was 51.92%.
Conclusion
2
CT-707 may inhibit the invasion and migration of hepatocellular carcinoma cells by inhibiting the activity of FAK/PI3K/Akt signaling pathway, thereby inhibiting cytoskeletal rearrangement and matrix metalloproteinase secretion.
Casadei GA , Foschi FG , Conti F , et al . Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals [J]. Dig Liver Dis , 2019 , 51 ( 5 ): 681 - 688 .
刘伟 , 杭春玖 , 薛同敏 , 等 . 黏着斑激酶与肝癌侵袭、转移的研究进展 [J]. 中华普通外科学文献(电子版) , 2015 , 9 ( 2 ): 79 - 82 .
Liu W , Hang CJ , Xue TM , et al . Progress on relationship between focal adhesion kinase and invasion metastasis of hepatoma [J]. Chin Arch Gen Surg (Electronic Edition) , 2015 , 9 ( 2 ): 79 - 82 .
Zhu H , Wang DD , Yuan T , et al . Multikinase inhibitor CT-707 targets liver cancer by interrupting the hypoxia-activated IGF-1R-YAP axis [J]. Cancer Res , 2018 , 78 ( 14 ): 3995 - 4006 .
姚红兵 , 郭威 , 吴嘉兴 , 等 . 新型黏着斑激酶抑制剂CT-707对肝癌细胞的影响及机制研究 [J]. 实用医学杂志 , 2020 , 36 ( 17 ): 2360 - 2364 .
Yao HB , Guo W , Wu JX , et al . The reserch of the influence and molecular mechanism of the adhesion kinase (FAK) inhibitor Ct-707 on liver cancer cells [J]. J Pract Med , 2020 , 36 ( 17 ): 2360 - 2364 .
Chen W , Zheng R , Baade P D , et al . Cancer statistics in China, 2015 [J]. Ca Cancer J Clin , 2016 , 66 ( 2 ): 115 - 132 .
Huang KGNBD . Correlation between FAK and EGF-Induced EMT in colorectal cancer cells [J]. Oncol , 2020 : 2020 - 5428920 .
Cao H , Xu E , Liu H , et al . Epithelial-mesenchymal transition in colorectal cancer metastasis: A system review [J]. Pathol Res Pract , 2015 , 211 ( 8 ): 557 - 569 .
李匡凡 , 杨真真 , 李勇 . 黏着斑激酶和磷酸酶基因蛋白在肝细胞癌中的表达及意义 [J]. 广东医学 , 2014 , 35 ( 14 ): 2216 - 2219 .
Li KF , Yang ZZ , Li Y . Expression and significance of focal adhesion kinase and phosphatase gene protein in hepatocellular carcinoma [J]. Guangdong Med J , 2014 , 35 ( 14 ): 2216 - 2219 .
Sieg DJ , Hauck CR , Ilic D , et al . FAK integrates growth-factor and integrin signals to promote cell migration [J]. Nature Cell Biol , 2000 , 2 ( 5 ): 249 - 256 .
Berdan CA , Ho R , Lehtola HS , et al . Parthenolide covalently targets and inhibits focal adhesion kinase in breast cancer cells [J]. Cell Chem Biol , 2019 , 26 ( 7 ): 1027 - 1035 .
Wang DD , Chen Y , Chen ZB , et al . CT-707, a novel FAK inhibitor, synergizes with cabozantinib to suppress hepatocellular carcinoma by blocking cabozantinib-induced FAK activation [J]. Mol Cancer Ther , 2016 , 15 ( 12 ): 2916 - 2925 .
Mansour MA , Asano E , Hyodo T , et al . Special AT-rich sequence-binding protein 2 suppresses invadopodia formation in HCT116 cells via palladin inhibition [J]. Exp Cell Res , 2015 , 332 ( 1 ): 78 - 88 .
曹文玺 , 金慧涵 , 季沅 . 缺氧对肝癌上皮细胞E-Cadherin、间质细胞Vimentin表达的影响 [J]. 中国当代医药 , 2015 , 22 ( 35 ): 4 - 6 .
Cao WX , Jin HH , Ji Y . Influence of hypoxia on expressions of E-Cadherin of epithelial cell and Vimentin of interstitial cell from liver cancer [J]. Chin Modern Med , 2015 , 22 ( 35 ): 4 - 6 .
Conlon GA , Murray GI . Recent advances in understanding the roles of matrix metalloproteinases in tumour invasion and metastasis [J]. J Pathol , 2019 , 247 ( 5 ): 629 - 640 .
Scheau C , Badarau IA , Costache R , et al . The role of matrix metalloproteinases in the epithelial-mesenchymal transition of hepatocellular carcinoma [J]. Analytical cellular pathology (Amsterdam) , 2019 , 2019 : 9423907 .
Peltonen R , Hagström J , Tervahartiala T , et al . High expression of MMP-9 in primary tumors and high preoperative mpo in serum predict improved prognosis in colorectal cancer with operable liver metastases [J]. Oncology , 2021 , 99 ( 3 ): 144 - 160 .
Yang Q , Ji G , Li J . STEAP2 is down-regulated in breast cancer tissue and suppresses PI3K/AKT signaling and breast cancer cell invasion in vitro and in vivo [J]. Cancer Biology & Therapy , 2020 , 21 ( 3 ): 278 - 291 .
Ryu D , Lee C . Expression quantitative trait loci for PI3K/AKT pathway [J]. Medicine (Baltimore) , 2017 , 96 ( 1 ): e5817 .
Liu S , Huang J , Zhang Y , et al . MAP2K4 interacts with Vimentin to activate the PI3K/AKT pathway and promotes breast cancer pathogenesis [J]. Aging (Albany NY) , 2019 , 11 ( 22 ): 10697 - 10710 .
Liu Q , Yang P , Tu K , et al . TPX2 knockdown suppressed hepatocellular carcinoma cell invasion via inactivating AKT signaling and inhibiting MMP2 and MMP9 expression [J]. Chin J Cancer Res , 2014 , 26 ( 4 ): 410 - 417 .
0
浏览量
265
下载量
2
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621
